648 related articles for article (PubMed ID: 11730396)
1. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.
Demeter LM; Hughes MD; Coombs RW; Jackson JB; Grimes JM; Bosch RJ; Fiscus SA; Spector SA; Squires KE; Fischl MA; Hammer SM
Ann Intern Med; 2001 Dec; 135(11):954-64. PubMed ID: 11730396
[TBL] [Abstract][Full Text] [Related]
2. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
[TBL] [Abstract][Full Text] [Related]
3. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.
Havlir DV; Marschner IC; Hirsch MS; Collier AC; Tebas P; Bassett RL; Ioannidis JP; Holohan MK; Leavitt R; Boone G; Richman DD
N Engl J Med; 1998 Oct; 339(18):1261-8. PubMed ID: 9791141
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and predictive value of intermittent viremia with combination hiv therapy.
Havlir DV; Bassett R; Levitan D; Gilbert P; Tebas P; Collier AC; Hirsch MS; Ignacio C; Condra J; Günthard HF; Richman DD; Wong JK
JAMA; 2001 Jul; 286(2):171-9. PubMed ID: 11448280
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up.
Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Jonas L; Meibohm A; Holder D; Schleif WA; Condra JH; Emini EA; Isaacs R; Chodakewitz JA; Richman DD
JAMA; 1998 Jul; 280(1):35-41. PubMed ID: 9660361
[TBL] [Abstract][Full Text] [Related]
6. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Richman DD; Valentine FT; Jonas L; Meibohm A; Emini EA; Chodakewitz JA
N Engl J Med; 1997 Sep; 337(11):734-9. PubMed ID: 9287228
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.
Pialoux G; Raffi F; Brun-Vezinet F; Meiffrédy V; Flandre P; Gastaut JA; Dellamonica P; Yeni P; Delfraissy JF; Aboulker JP
N Engl J Med; 1998 Oct; 339(18):1269-76. PubMed ID: 9791142
[TBL] [Abstract][Full Text] [Related]
8. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
9. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
Montaner JS; DeMasi R; Hill AM
AIDS; 1998 Mar; 12(5):F23-8. PubMed ID: 9543436
[TBL] [Abstract][Full Text] [Related]
10. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
[TBL] [Abstract][Full Text] [Related]
11. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
[TBL] [Abstract][Full Text] [Related]
12. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).
Vibhagool A; Cahn P; Schechter M; Smaill F; Soto-Ramirez L; Carosi G; Montroni M; Pharo CE; Jordan JC; Thomas NE; Pearce G
Curr Med Res Opin; 2004 Jul; 20(7):1103-14. PubMed ID: 15265255
[TBL] [Abstract][Full Text] [Related]
13. Summaries for patients. Predictors of outcomes in patients with HIV infection treated with indinavir, zidovudine, and lamivudine.
Ann Intern Med; 2001 Dec; 135(11):S-59. PubMed ID: 11759663
[No Abstract] [Full Text] [Related]
14. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
Cohen Stuart JW; Schuurman R; Burger DM; Koopmans PP; Sprenger HG; Juttmann JR; Richter C; Meenhorst PL; Hoetelmans RM; Kroon FP; Bravenboer B; Hamann D; Boucher CA; Borleffs JC
AIDS; 1999 May; 13(7):F53-8. PubMed ID: 10357371
[TBL] [Abstract][Full Text] [Related]
15. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
[TBL] [Abstract][Full Text] [Related]
16. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
Joly V; Flandre P; Meiffredy V; Brun-Vezinet F; Gastaut JA; Goujard C; Remy G; Descamps D; Ruffault A; Certain A; Aboulker JP; Yeni P;
Antimicrob Agents Chemother; 2002 Jun; 46(6):1906-13. PubMed ID: 12019107
[TBL] [Abstract][Full Text] [Related]
19. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
Jankelevich S; Mueller BU; Mackall CL; Smith S; Zwerski S; Wood LV; Zeichner SL; Serchuck L; Steinberg SM; Nelson RP; Sleasman JW; Nguyen BY; Pizzo PA; Yarchoan R
J Infect Dis; 2001 Apr; 183(7):1116-20. PubMed ID: 11237839
[TBL] [Abstract][Full Text] [Related]
20. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.
Gulick RM; Mellors JW; Havlir D; Eron JJ; Meibohm A; Condra JH; Valentine FT; McMahon D; Gonzalez C; Jonas L; Emini EA; Chodakewitz JA; Isaacs R; Richman DD
Ann Intern Med; 2000 Jul; 133(1):35-9. PubMed ID: 10877738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
